MX2018001435A - Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. - Google Patents
Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.Info
- Publication number
- MX2018001435A MX2018001435A MX2018001435A MX2018001435A MX2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A
- Authority
- MX
- Mexico
- Prior art keywords
- lennox
- fenfluramine
- syndrome
- methods
- gastaut syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Paper (AREA)
Abstract
Un método de tratamiento y/o prevención de síntomas del síndrome de Lennox-Gastaut (LGS) también conocido como Síndrome de Lennox en un paciente, tal como un paciente previamente diagnosticado con el Síndrome de Lennox, mediante la administración de una dosis efectiva de fenfluramina o sus sales farmacéuticamente aceptables a dicho paciente. Los pacientes con Síndrome de Lennox son tratados con una dosis preferida de menos de aproximadamente 2.0 a aproximadamente 0.01 mg / kg / día.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562209090P | 2015-08-24 | 2015-08-24 | |
PCT/US2016/048470 WO2017035267A1 (en) | 2015-08-24 | 2016-08-24 | Methods of treating lennox-gastaut syndrome using fenfluramine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001435A true MX2018001435A (es) | 2018-04-20 |
Family
ID=58101064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001435A MX2018001435A (es) | 2015-08-24 | 2016-08-24 | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. |
Country Status (20)
Country | Link |
---|---|
US (4) | US20170056344A1 (es) |
EP (2) | EP3340971B1 (es) |
JP (1) | JP6895949B2 (es) |
KR (3) | KR20180054584A (es) |
CN (3) | CN108135865A (es) |
AU (1) | AU2016312526B2 (es) |
BR (1) | BR112018002046A2 (es) |
CA (1) | CA2993665C (es) |
DK (1) | DK3340971T3 (es) |
FI (1) | FI3340971T3 (es) |
HR (1) | HRP20240508T1 (es) |
IL (1) | IL257276B (es) |
LT (1) | LT3340971T (es) |
MX (1) | MX2018001435A (es) |
PL (1) | PL3340971T3 (es) |
PT (1) | PT3340971T (es) |
RU (1) | RU2740919C2 (es) |
SI (1) | SI3340971T1 (es) |
WO (1) | WO2017035267A1 (es) |
ZA (1) | ZA201800499B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10647465B2 (en) | 2010-11-12 | 2020-05-12 | Niagara Bottling, Llc | Perform extended finish for processing light weight ecologically beneficial bottles |
JP2013543805A (ja) | 2010-11-12 | 2013-12-09 | ナイアガラ・ボトリング・エルエルシー | 軽量ボトルを加工するための伸長仕上げされたプリフォーム |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
CA3007673A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
EP4293009A3 (en) | 2015-12-22 | 2024-02-21 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
US20180055789A1 (en) | 2016-08-24 | 2018-03-01 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht2b agonists and methods of using same |
US20180092864A1 (en) * | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
MX2019013279A (es) * | 2017-05-09 | 2020-01-15 | Zogenix International Ltd | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. |
US20190091179A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
CA3097335A1 (en) * | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
WO2020014075A1 (en) * | 2018-07-10 | 2020-01-16 | Zogenix International Limited | Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension |
US11597556B2 (en) | 2018-07-30 | 2023-03-07 | Niagara Bottling, Llc | Container preform with tamper evidence finish portion |
SG11202104378SA (en) * | 2018-11-19 | 2021-05-28 | Zogenix International Ltd | Methods of treating rett syndrome using fenfluramine |
EP3930841A4 (en) * | 2019-02-25 | 2022-11-30 | Zogenix International Limited | FORMULATION TO IMPROVE SEIZURE CONTROL |
EP4031114A1 (en) * | 2019-09-17 | 2022-07-27 | Zogenix International Limited | Methods of treating epileptic patients with fenfluramine |
US20210299064A1 (en) * | 2020-02-05 | 2021-09-30 | Zogenix International Limited | Method of treating patients with lennox-gastaut syndrome |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1413070A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of - norfenfluramine and - fenfluramine and salts thereof |
GB1413078A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof |
IT1238686B (it) | 1990-02-09 | 1993-09-01 | Lab Mag Spa | Procedimento per la preparazione di levo e destro fenfluramina |
EP1888030A1 (en) * | 2005-05-25 | 2008-02-20 | Janssen Pharmaceutica N.V. | Pediatric formulation of topiramate |
US20070021501A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods of treating epileptogenesis |
GB0515090D0 (en) * | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
PE20110852A1 (es) * | 2008-10-30 | 2011-11-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida |
US20110212171A1 (en) * | 2010-01-08 | 2011-09-01 | Eurand, Inc. | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
WO2011132171A1 (en) * | 2010-04-23 | 2011-10-27 | Piramal Life Sciences Limited | Nitric oxide releasing prodrugs of therapeutic agents |
US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
ES2813450T3 (es) * | 2013-08-19 | 2021-03-23 | Univ California | Compuestos y métodos para tratar un trastorno epiléptico |
-
2016
- 2016-08-24 KR KR1020187005840A patent/KR20180054584A/ko not_active IP Right Cessation
- 2016-08-24 MX MX2018001435A patent/MX2018001435A/es unknown
- 2016-08-24 CN CN201680049517.7A patent/CN108135865A/zh active Pending
- 2016-08-24 JP JP2018510511A patent/JP6895949B2/ja active Active
- 2016-08-24 BR BR112018002046A patent/BR112018002046A2/pt not_active Application Discontinuation
- 2016-08-24 PL PL16840062.0T patent/PL3340971T3/pl unknown
- 2016-08-24 US US15/246,346 patent/US20170056344A1/en not_active Abandoned
- 2016-08-24 AU AU2016312526A patent/AU2016312526B2/en active Active
- 2016-08-24 SI SI201631816T patent/SI3340971T1/sl unknown
- 2016-08-24 KR KR1020227005011A patent/KR102481631B1/ko active IP Right Grant
- 2016-08-24 RU RU2018108202A patent/RU2740919C2/ru active
- 2016-08-24 WO PCT/US2016/048470 patent/WO2017035267A1/en active Application Filing
- 2016-08-24 HR HRP20240508TT patent/HRP20240508T1/hr unknown
- 2016-08-24 EP EP16840062.0A patent/EP3340971B1/en active Active
- 2016-08-24 EP EP24161855.2A patent/EP4397372A3/en active Pending
- 2016-08-24 FI FIEP16840062.0T patent/FI3340971T3/fi active
- 2016-08-24 DK DK16840062.0T patent/DK3340971T3/da active
- 2016-08-24 KR KR1020227045101A patent/KR102615486B1/ko active IP Right Grant
- 2016-08-24 LT LTEPPCT/US2016/048470T patent/LT3340971T/lt unknown
- 2016-08-24 CA CA2993665A patent/CA2993665C/en active Active
- 2016-08-24 CN CN202211037242.9A patent/CN115350168A/zh active Pending
- 2016-08-24 CN CN202210746238.3A patent/CN115192575A/zh active Pending
- 2016-08-24 PT PT168400620T patent/PT3340971T/pt unknown
-
2018
- 2018-01-24 ZA ZA2018/00499A patent/ZA201800499B/en unknown
- 2018-01-31 IL IL257276A patent/IL257276B/en unknown
-
2020
- 2020-05-01 US US16/864,955 patent/US20200253895A1/en active Pending
-
2024
- 2024-01-19 US US18/418,121 patent/US20240245631A1/en active Pending
- 2024-01-19 US US18/418,133 patent/US20240238222A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
MX2018002906A (es) | Metodos de tratamiento de trastornos del desarrollo con pipradrol. | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
PH12015502500B1 (en) | Bacteriophage therapy | |
WO2019067405A3 (en) | FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
MX2019004200A (es) | Terapia de combinacion. | |
MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
MX2022004785A (es) | Metodos y composiciones para el tratamiento del sindrome de rett. | |
PH12017501918A1 (en) | Multi-peptide composition | |
MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
MX2016011002A (es) | Tratamiento de angioedema hereditario con inhibidor c1. |